Stevanato Group (STVN) announced its collaboration with Thermo Fisher Scientific (TMO) to bring to the market a fully integrated on-body delivery system platform for subcutaneous administration. The semi-reusable drug delivery device will provide micro-precision basal doses and full-content bolus injections as a highly flexible and customizable platform for administering a wide range of therapies. The collaboration brings the ability to deliver small molecules and biologics, including large volumes, subcutaneously at home, closer to patients, improving adherence and effectiveness of pharmacological treatments. Along with the proprietary device platform, Stevanato Group will offer pre-sterilized EZ-fill cartridges as drug containment solutions and assembly equipment, while Thermo Fisher will provide fill-and-finish and final assembly services.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on STVN:
- Stevanato teams with CDMO Recipharm on pre-fillable syringe production
- Stevanato Group price target raised to $27 from $21 at Wells Fargo
- Stevanato Group price target raised to $30 from $22 at Citi
- Stevanato Group sees 2023 adjusted EPS EUR0.58-EUR0.62 vs. EUR0.56 in 2022
- Stevanato Group reports Q4 adjusted EPS EUR0.18 vs. EUR0.17 last year